Richard Daniell Sells 115,468 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) VP Richard Daniell sold 115,468 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the sale, the vice president owned 48,384 shares in the company, valued at approximately $1,387,653.12. This trade represents a 70.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $29.80 on Friday. The stock has a market cap of $34.18 billion, a P/E ratio of 49.67, a P/E/G ratio of 1.79 and a beta of 0.67. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $30.20. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The company has a fifty day simple moving average of $23.43 and a 200 day simple moving average of $19.60.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on TEVA shares. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Barclays assumed coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday. They set an “overweight” rating and a $35.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, The Goldman Sachs Group increased their target price on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $30.25.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Phoenix Financial Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after acquiring an additional 3,533,800 shares in the last quarter. Ion Asset Management Ltd. boosted its position in Teva Pharmaceutical Industries by 6.5% during the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock valued at $599,945,000 after purchasing an additional 2,383,500 shares during the last quarter. Menora Mivtachim Holdings LTD. grew its stake in Teva Pharmaceutical Industries by 1.1% in the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after purchasing an additional 427,000 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Teva Pharmaceutical Industries by 12.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after purchasing an additional 4,306,363 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 13.6% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock worth $658,161,000 after purchasing an additional 3,896,790 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.